[Urgent] Starlink Set For The Largest IPO In History?

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.

Click here now for the urgent details on this hidden play.

Warren Whitehead Biography and Net Worth

Director of Aptose Biosciences

Mr. Warren Whitehead is a Chartered Professional Accountant (CPA) and Certified Management Accountant (CMA) who has held multiple senior financial management positions in several biotechnology and pharmaceutical companies. Mr. Whitehead was the former Chairman and Board Member of Plantform Corporation and a former Board Member of Telesta Therapeutics (TSX), which was acquired by Prometic Life Sciences in 2016. He served as the Chief Financial Officer of ProMIS Neurosciences Inc. (formerly Amorfix Life Sciences Ltd.) from 2013 to 2015, a TSX-listed company targeting detection and effective treatment of Alzheimer’s disease and amyotrophic lateral sclerosis. Previously, from 2006 to 2008, he was the Chief Financial Officer of Arius Research Inc., a TSX-listed company developing anti-cancer antibodies, where he provided financial guidance and leadership during the acquisition of Arius by Roche in 2008. He was also the former Chief Financial Officer of Labopharm Inc. from 2000 to 2006, where he completed a series of public equity financings, including a cross-border Nasdaq offering. Other positions include Chief Financial Officer of Resolution Pharmaceuticals Inc., and a position in finance and business development at Glaxo Canada (now GlaxoSmithKline). Mr. Whitehead holds an MBA and BComm from the University of Windsor and a BA from the University of Western Ontario.

What is Warren Whitehead's net worth?: The estimated net worth of Warren Whitehead is at least $624.84 as of June 21st, 2021. Mr. Whitehead owns 1,640 shares of Aptose Biosciences stock worth more than $625 as of November 15th. This net worth approximation does not reflect any other investments that Mr. Whitehead may own. Learn More about Warren Whitehead's net worth.
How do I contact Warren Whitehead?: The corporate mailing address for Mr. Whitehead and other Aptose Biosciences executives is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. Aptose Biosciences can also be reached via phone at 858-926-2730 and via email at [email protected]. Learn More on Warren Whitehead's contact information.
Has Warren Whitehead been buying or selling shares of Aptose Biosciences?: Warren Whitehead has not been actively trading shares of Aptose Biosciences in the last ninety days. Most recently, Warren Whitehead sold 1,026 shares of the business's stock in a transaction on Monday, June 21st. The shares were sold at an average price of $50.25, for a transaction totalling $51,556.50. Following the completion of the sale, the director now directly owns 1,640 shares of the company's stock, valued at $82,410. Learn More on Warren Whitehead's trading history.
Who are Aptose Biosciences' active insiders?: Aptose Biosciences' insider roster includes Rafael Bejar (VP), Denis Burger (Director), Erich Platzer (Director), William Rice (CEO), Warren Whitehead (Director), and Donald Wilson, Jr. (Major Shareholder). Learn More on Aptose Biosciences' active insiders.

Warren Whitehead Insider Trading History at Aptose Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/21/2021	Sell	1,026	$50.25	$51,556.50	1,640
12/22/2020	Sell	1,333	$60.90	$81,179.70	4,000
6/23/2020	Sell	1,200	$106.65	$127,980.00	3,416

Warren Whitehead Buying and Selling Activity at Aptose Biosciences

Aptose Biosciences Company Overview

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Today's Range

Now: $0.38

$0.37

$0.39

50 Day Range

MA: $0.38

$0.35

$0.41

2 Week Range

Now: $0.38

$0.33

$2.91

Volume

52,166 shs

Average Volume

75,008 shs

Market Capitalization

$6.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26